A two-cohort phase 1 study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine and erlotinib during radiotherapy for unresectable pancreatic carcinoma

OBJECTIVES: Gemcitabine is a potent radiosensitizer. When combined with standard radiotherapy (XRT) the gemcitabine dose must be reduced to about 10% of its conventional dose. Oxaliplatin and erlotinib also have radiosensitizing properties. In vitro, oxaliplatin and gemcitabine have demonstrated syn...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Raftery, Laura, Tepper, Joel E, Goldberg, Richard M., Blackstock, A. William, Aklilu, Mebea, Bernard, Stephen A., Ivanova, Anastasia, Davies, Janine M., O’Neil, Bert H.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3900023/
https://ncbi.nlm.nih.gov/pubmed/22547007
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/COC.0b013e3182467f22
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados